CBIO
Crescent Biopharma, Inc.
NASDAQ: CBIO · HEALTHCARE · BIOTECHNOLOGY
$22.37
+6.83% today
Updated 2026-04-30
Market cap
$755.46M
P/E ratio
—
P/S ratio
69.67x
EPS (TTM)
$-12.81
Dividend yield
—
52W range
$9 – $29
Volume
0.2M
Crescent Biopharma, Inc. (CBIO) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-844.00%
ROE
-160.70%
ROA
-69.20%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2011 | $3.81M | $-6.11M | 97.80% | -159.54% | -160.29% |
| 2012 | $15.26M | $3.66M | 100.00% | 23.82% | 23.96% |
| 2013 | $3.99M | $-10.61M | 100.00% | -265.65% | -265.63% |
| 2014 | $15.03M | $-11.12M | 100.00% | -74.13% | -74.01% |
| 2015 | $20.07M | $-12.77M | 100.00% | -63.70% | -63.62% |
| 2016 | $18500.00 | $-31.81M | 100.00% | -172,505.32% | -171,945.07% |
| 2017 | — | $-33.28M | — | — | — |
| 2018 | — | $-48.27M | — | — | — |
| 2019 | — | $-54.12M | — | — | — |
| 2020 | $10.16M | $-51.03M | 100.00% | -506.84% | -502.09% |
| 2021 | $1.16M | $-63.43M | 100.00% | -5,470.69% | -5,468.98% |
| 2022 | $75000.00 | $-46.69M | 100.00% | -63,204.43% | -62,251.74% |
| 2023 | $10000.00 | $-36.90M | 100.00% | -392,752.93% | -368,994.20% |
| 2024 | — | $-71.47M | — | — | — |
| 2025 | $10.84M | $-149.94M | 99.23% | -1,407.52% | -1,382.72% |